Pierre Blanchard, Radiation Oncology Clinical section chief at Gustave Roussy Cancer Institute, shared on X:
“Dr Pobel at ESMO2024 presenting the molecular analysis of the PEACE 1 trial. Identifies molecular phenotypes and prognostic markers but no interaction with abiraterone efficacy Major undertaking by GETUG, Gustave Roussy.”
Source: Pierre Blanchard/X
More posts featuring ESMO24 on oncodaily.com
